tiprankstipranks
arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR (BR:A1RG34)
:A1RG34
Brazil Market
A1RG34
arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR
RESEARCH TOOLSreports

arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR (A1RG34) Price & Analysis

― Followers

A1RG34 Stock Chart & Stats

R$176.94
R$5.73(3.35%)
―
--
Day’s Range― - ―
52-Week RangeR$1.00 - R$248.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)151.00
Market Cap
R$272.82B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Oct 22, 2026
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,539,223,100
10 Day Avg. Volume56
30 Day Avg. Volume151
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A

arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR News

Argenx resumed with a Buy at Guggenheim
Argenx resumed with a Buy at Guggenheim
Guggenheim resumed coverage of Argenx (ARGX) with a Buy rating and $1,185 price target Published first on TheFly...
3d ago
ARGX
Corning removed from ‘US 1 List’ at BofA
Corning removed from ‘US 1 List’ at BofA
BofA is renewing Argenx (ARGX) for a new term following 52 weeks on the firm’s “US 1 List”...
10d ago
GLW
ARGX
First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush
First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush
Wedbush raised the firm’s price target on First Tracks Biotherapeutics to $60 from $30 and keeps an Outperform...
11d ago
ARGX
FBRX
Argenx price target raised to $1,050 from $1,000 at Wedbush
Argenx price target raised to $1,050 from $1,000 at Wedbush
Wedbush raised the firm’s price target on Argenx (ARGX) to $1,050 from $1,000 and keeps an Outperform rating...
11d ago
ARGX
FBRX
After Forte acquisition, H.C. Wainwright says First Tracks could be target
After Forte acquisition, H.C. Wainwright says First Tracks could be target
After Argenx (ARGX) announced a deal to acquire Forte (FBRX) for a price of $77 per share, a...
11d ago
ARGX
FBRX
Midday Fly By: Argenx to buy Forte, Nvidia in talks for $250B OpenAI backstop
Midday Fly By: Argenx to buy Forte, Nvidia in talks for $250B OpenAI backstop
The major averages were mixed near noon, with the Dow higher and the S&P 500 and Nasdaq in...
11d ago
F
GM
Forte Biosciences downgraded to In Line from Outperform at Evercore ISI
Forte Biosciences downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Forte Biosciences (FBRX) to In Line from Outperform with a price target of $77, up...
11d ago
ARGX
FBRX
Video: Jefferies more bullish on Ford and GM
Video: Jefferies more bullish on Ford and GM
The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...
12d ago
F
T
Morning Movers: Ensign Group surges following second quarter results
Morning Movers: Ensign Group surges following second quarter results
Stock futures are sharply higher Monday as investors return from the weekend encouraged by easing geopolitical tensions and...
12d ago
AMR
AZN
Argenx price target raised to $932 from $867 at Baird
Argenx price target raised to $932 from $867 at Baird
Baird raised the firm’s price target on Argenx (ARGX) to $932 from $867 and keeps a Neutral rating...
12d ago
ARGX
argenx Buy Rating Reaffirmed as FB102 Acquisition and Vyvgart Momentum Support Unchanged $940 Price Target
argenx Buy Rating Reaffirmed as FB102 Acquisition and Vyvgart Momentum Support Unchanged $940 Price Target
Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Argenx Se and keeping the price target...
11d ago
ARGX
Argenx Buy Rating Reiterated as Forte Biosciences Deal Broadens Pipeline; $1,088 Price Target Maintained
Argenx Buy Rating Reiterated as Forte Biosciences Deal Broadens Pipeline; $1,088 Price Target Maintained
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Argenx...
11d ago
ARGX

A1RG34 FAQ

What was arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s price range in the past 12 months?
arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR lowest stock price was R$1.00 and its highest was R$248.80 in the past 12 months.
    What is arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s market cap?
    arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s market cap is R$272.82B.
      When is arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s upcoming earnings report date?
      arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s upcoming earnings report date is Oct 22, 2026 which is in 75 days.
        How were arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s earnings last quarter?
        Currently, no data Available
        Is arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR overvalued?
        According to Wall Street analysts arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR pay dividends?
          arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR does not currently pay dividends.
          What is arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s EPS estimate?
          arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR have?
          arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR has 1,539,223,100 shares outstanding.
            What happened to arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR?
            Currently, no hedge funds are holding shares in BR:A1RG34
            What is the TipRanks Smart Score and how is it calculated?
            Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

              arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR (A1RG34) Earnings & Revenues

              Historic Earnings Reports
              Similar Stocks
              Company
              Price & Change
              Follow
              A1LN34
              Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh
              ―
              ―
              B1ME34
              BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR
              ―
              ―
              REGN34
              Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh
              ―
              ―
              T1EV34
              Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR
              ―
              ―
              TAKP34
              Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR
              ―
              ―
              Compare BR:A1RG34 Stocks >
              Popular Stocks